Concepedia

Tiffany Palmer

TP

Statistics

Publications

5

Citations

819

H-Index

5

Active since

2013

Affiliations

AstraZeneca (United States)(Current)

Tiffany Palmer is an author at AstraZeneca (United States) specializing in medical microbiology, microbiology, and antimicrobial resistance.

Publications per year

2013–2024

5

Publications

5

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

David E. Ehmann, Haris Jahić, Philip L. Ross et al. · Journal of Biological Chemistry · 2013 · 355 citations · Full text

, , +16

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir et al. · Nature Microbiology · 2017 · 271 citations

, , +16

Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in <i>Pseudomonas aeruginosa</i> strains containing derepressed AmpC

Sushmita D. Lahiri, Grant K. Walkup, James Whiteaker et al. · Journal of Antimicrobial Chemotherapy · 2015 · 127 citations · Full text

, , +17

Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914

Günther Kern, Tiffany Palmer, David E. Ehmann et al. · Journal of Biological Chemistry · 2015 · 56 citations · Full text

, , +17

Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

Amaya López-Pascual, Joan Salvador Russo-Cabrera, Nuria Ardaiz et al. · Clinical Science · 2024 · 10 citations · Full text

, , +17

1–5 of 5